{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:11:19Z","timestamp":1787249479011,"version":"build-2736575974"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10787-022-01072-1","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T13:05:12Z","timestamp":1666443912000},"page":"2051-2061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders"],"prefix":"10.1007","volume":"30","author":[{"given":"Heena","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchal","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarjot Kaur","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"issue":"3","key":"1072_CR1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/07391102.2017.1288659","volume":"36","author":"SA Amin","year":"2018","unstructured":"Amin SA, Bhargava S, Adhikari N, Gayen S, Jha T (2018) Exploring pyrazolo [3, 4-d] pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques. J Biomol Struct Dyn 36(3):590\u2013608. https:\/\/doi.org\/10.1080\/07391102.2017.1288659","journal-title":"J Biomol Struct Dyn"},{"issue":"6","key":"1072_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.neuint.2004.03.015","volume":"45","author":"AT Bender","year":"2004","unstructured":"Bender AT, Beavo JA (2004) Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem Int 45(6):853\u2013857. https:\/\/doi.org\/10.1016\/j.neuint.2004.03.015","journal-title":"Neurochem Int"},{"issue":"4","key":"1072_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1517\/13543776.2012.674514","volume":"22","author":"A Blokland","year":"2012","unstructured":"Blokland A, Menniti FS, Prickaerts J (2012) PDE inhibition and cognition enhancement. Expert Opin Ther Pat 22(4):349\u2013354. https:\/\/doi.org\/10.1517\/13543776.2012.674514","journal-title":"Expert Opin Ther Pat"},{"issue":"24","key":"1072_CR4","doi-asserted-by":"publisher","first-page":"14188","DOI":"10.1073\/pnas.93.24.14188","volume":"93","author":"TJ Bloom","year":"1996","unstructured":"Bloom TJ, Beavo JA (1996) Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci 93(24):14188\u201314192. https:\/\/doi.org\/10.1073\/pnas.93.24.14188","journal-title":"Proc Natl Acad Sci"},{"key":"1072_CR5","doi-asserted-by":"publisher","unstructured":"Bolger GB (2017) The PDE4 cAMP-specific phosphodiesterases: targets for drugs with antidepressant and memory-enhancing action. In: Phosphodiesterases: CNS functions and diseases, pp 63\u2013102. https:\/\/doi.org\/10.1016\/S0065-7743(07)42001-2","DOI":"10.1016\/S0065-7743(07)42001-2"},{"issue":"12","key":"1072_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/iub.1104","volume":"64","author":"E Bollen","year":"2012","unstructured":"Bollen E, Prickaerts J (2012) Phosphodiesterases in neurodegenerative disorders. IUBMB Life 64(12):965\u2013970. https:\/\/doi.org\/10.1002\/iub.1104","journal-title":"IUBMB Life"},{"issue":"2","key":"1072_CR201","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/npp.2009.144","volume":"35","author":"D Boulay","year":"2010","unstructured":"Boulay D, Bergis O, Avenet P, Griebel G (2010) The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35(2):416\u2013427. https:\/\/doi.org\/10.1038\/npp.2009.144","journal-title":"Neuropsychopharmacology"},{"key":"1072_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0065-7743(07)42001-2","volume":"42","author":"NJ Brandon","year":"2007","unstructured":"Brandon NJ, Rotella DP (2007) Potential CNS applications for phosphodiesterase enzyme inhibitors. Annu Rep Med Chem 42:3\u201312. https:\/\/doi.org\/10.1016\/S0065-7743(07)42001-2","journal-title":"Annu Rep Med Chem"},{"key":"1072_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108694","volume":"196","author":"Y Chen","year":"2021","unstructured":"Chen Y, Wang H, Wang WZ, Wang D, Skaggs K, Zhang HT (2021) Phosphodiesterase 7 (PDE7): a unique drug target for central nervous system diseases. Neuropharmacology 196:108694. https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108694","journal-title":"Neuropharmacology"},{"issue":"Pt 8","key":"1072_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain 122(Pt 8):1437\u20131448. https:\/\/doi.org\/10.1093\/brain\/122.8.1437","journal-title":"Brain"},{"issue":"1","key":"1072_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ncl.2014.09.003","volume":"33","author":"P Dayalu","year":"2015","unstructured":"Dayalu P, Albin RL (2015) Huntington disease: pathogenesis and treatment. Neurol Clin 33(1):101\u2013114. https:\/\/doi.org\/10.1016\/j.ncl.2014.09.003","journal-title":"Neurol Clin"},{"issue":"9","key":"1072_CR11","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","volume":"26","author":"S Delhaye","year":"2021","unstructured":"Delhaye S, Bardoni B (2021) Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. Mol Psychiatry 26(9):4570\u20134582. https:\/\/doi.org\/10.1038\/s41380-020-00997-9","journal-title":"Mol Psychiatry"},{"issue":"8","key":"1072_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071279","volume":"8","author":"D Demirbas","year":"2013","unstructured":"Demirbas D, Wyman AR, Shimizu-Albergine M, Cakici O, Beavo JA, Hoffman CS (2013) A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition. PLoS ONE 8(8):e71279. https:\/\/doi.org\/10.1371\/journal.pone.0071279","journal-title":"PLoS ONE"},{"key":"1072_CR13","doi-asserted-by":"publisher","unstructured":"Dorner-Ciossek C, Kroker KS, Rosenbrock H (2017) Role of PDE9 in cognition. In: Phosphodiesterases: CNS functions and diseases, pp 231\u2013254. https:\/\/doi.org\/10.1007\/978-3-319-58811-7_9","DOI":"10.1007\/978-3-319-58811-7_9"},{"key":"1072_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jad.2019.11.114","volume":"264","author":"E Duarte-Silva","year":"2020","unstructured":"Duarte-Silva E, Chaves Filho AJ, Barichello T, Quevedo J, Macedo D, Peixoto C (2020) Phosphodiesterase-5 inhibitors: shedding new light on the darkness of depression? J Affect Disord 264:138\u2013149. https:\/\/doi.org\/10.1016\/j.jad.2019.11.114","journal-title":"J Affect Disord"},{"key":"1072_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109592","volume":"70","author":"R Farmer","year":"2020","unstructured":"Farmer R, Burbano SD, Patel NS, Sarmiento A, Smith AJ, Kelly MP (2020) Phosphodiesterases PDE2A and PDE10A both change mRNA expression in the human brain with age, but only PDE2A changes in a region-specific manner with psychiatric disease. Cell Signal 70:109592. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109592","journal-title":"Cell Signal"},{"issue":"3","key":"1072_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2174\/1381612820666140826113957","volume":"21","author":"FR Fusco","year":"2015","unstructured":"Fusco FR, Giampa C (2015) Phosphodiesterases as therapeutic targets for Huntington\u2019s disease. Curr Pharm Des 21(3):365\u2013377. https:\/\/doi.org\/10.2174\/1381612820666140826113957","journal-title":"Curr Pharm Des"},{"key":"1072_CR17","doi-asserted-by":"publisher","unstructured":"Fusco FR, Paldino E (2017) Role of phosphodiesterases in huntington\u2019s disease. In: Phosphodiesterases: CNS functions and diseases, pp 285\u2013304. https:\/\/doi.org\/10.1007\/978-3-319-58811-7_11","DOI":"10.1007\/978-3-319-58811-7_11"},{"issue":"3","key":"1072_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","volume":"53","author":"AS Galanopoulou","year":"2012","unstructured":"Galanopoulou AS, Buckmaster PS, Staley KJ, Mosh\u00e9 SL, Perucca E, Engel J Jr, L\u00f6scher W, Noebels JL, Pitk\u00e4nen A, Stables J, White HS, American Epilepsy Society Basic Science Committee and the International League Against Epilepsy Working Group on Recommendations for Preclinical Epilepsy Drug Discovery, M (2012) Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 53(3):571\u2013582. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03391.x","journal-title":"Epilepsia"},{"issue":"2","key":"1072_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1471-4159.2007.05137.x","volume":"105","author":"K Gharami","year":"2008","unstructured":"Gharami K, Xie Y, An JJ, Tonegawa S, Xu B (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington\u2019s disease phenotypes in mice. J Neurochem 105(2):369\u2013379. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05137.x","journal-title":"J Neurochem"},{"issue":"5","key":"1072_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064037","volume":"8","author":"C Giamp\u00e0","year":"2013","unstructured":"Giamp\u00e0 C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE 8(5):e64037. https:\/\/doi.org\/10.1371\/journal.pone.0064037","journal-title":"PLoS ONE"},{"issue":"10","key":"1072_CR21","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1517\/13543776.18.10.1127","volume":"18","author":"C Gil","year":"2008","unstructured":"Gil C, Campillo NE, Perez DI, Martinez A (2008) PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Ther Pat 18(10):1127\u20131139. https:\/\/doi.org\/10.1517\/13543776.18.10.1127","journal-title":"Expert Opin Ther Pat"},{"issue":"5","key":"1072_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/hmg\/ddg046","volume":"12","author":"S Gines","year":"2003","unstructured":"Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice. Hum Mol Genet 12(5):497\u2013508. https:\/\/doi.org\/10.1093\/hmg\/ddg046","journal-title":"Hum Mol Genet"},{"issue":"1","key":"1072_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cns.12655","volume":"23","author":"M Golpich","year":"2017","unstructured":"Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A (2017) Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci Ther 23(1):5\u201322. https:\/\/doi.org\/10.1111\/cns.12655","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"1072_CR209","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/13576280600937911","volume":"19","author":"JJ Guilbert","year":"2006","unstructured":"Guilbert JJ (2006) The World Health Report 2006: working together for health. Educ Health (Abingdon) 19(3):385\u2013387. https:\/\/doi.org\/10.1080\/13576280600937911","journal-title":"Educ Health (Abingdon)"},{"issue":"1","key":"1072_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13311-014-0309-7","volume":"12","author":"ME Gurney","year":"2015","unstructured":"Gurney ME, D\u2019Amato EC, Burgin AB (2015) Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer\u2019s disease. Neurotherapeutics 12(1):49\u201356. https:\/\/doi.org\/10.1007\/s13311-014-0309-7","journal-title":"Neurotherapeutics"},{"key":"1072_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","volume":"87","author":"PR Heckman","year":"2018","unstructured":"Heckman PR, Blokland A, Bollen EP, Prickaerts J (2018) Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations. Neurosci Biobehav Rev 87:233\u2013254. https:\/\/doi.org\/10.1016\/j.neubiorev.2018.02.007","journal-title":"Neurosci Biobehav Rev"},{"key":"1072_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.472","author":"JM Hetman","year":"2000","unstructured":"Hetman JM, Soderling SH, Glavas NA, Beavo JA (2000) Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.97.1.472","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1072_CR202","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.biopsych.2009.08.030","volume":"67","author":"M Ikeda","year":"2010","unstructured":"Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, Yamanouchi Y, Kinoshita Y, Hashimoto R, Williams HJ, Takeda M (2010) Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 67(3):263\u2013269. https:\/\/doi.org\/10.1016\/j.biopsych.2009.08.030","journal-title":"Biol Psychiatry"},{"issue":"7","key":"1072_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2174\/0929867324666170116125159","volume":"24","author":"A Jankowska","year":"2017","unstructured":"Jankowska A, Swierczek A, Chlon-Rzepa G, Pawlowski M, Wyska E (2017) PDE7-selective and dual inhibitors: advances in chemical and biological research. Curr Med Chem 24(7):673\u2013700. https:\/\/doi.org\/10.2174\/0929867324666170116125159","journal-title":"Curr Med Chem"},{"issue":"4","key":"1072_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1165\/rcmb.2017-0294OC","volume":"58","author":"TB Johnstone","year":"2018","unstructured":"Johnstone TB, Smith KH, Koziol-White CJ, Li F, Kazarian AG, Corpuz ML, Shumyatcher M, Ehlert FJ, Himes BE, Panettieri RA Jr, Ostrom RS (2018) PDE8 is expressed in human airway smooth muscle and selectively regulates cAMP signaling by \u03b22-adrenergic receptors and adenylyl cyclase 6. Am J Respir Cell Mol Biol 58(4):530\u2013541. https:\/\/doi.org\/10.1165\/rcmb.2017-0294OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1072_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","volume":"42","author":"MP Kelly","year":"2018","unstructured":"Kelly MP (2018) Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cell Signal 42:281\u2013291. https:\/\/doi.org\/10.1016\/j.cellsig.2017.11.004","journal-title":"Cell Signal"},{"issue":"11","key":"1072_CR30","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/jphp.13336","volume":"72","author":"H Khan","year":"2020","unstructured":"Khan H, Kashyap A, Kaur A, Singh TG (2020) Pharmacological postconditioning: a molecular aspect in ischemic injury. J Pharm Pharmacol 72(11):1513\u20131527. https:\/\/doi.org\/10.1111\/jphp.13336","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"1072_CR31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s43440-021-00258-8","volume":"73","author":"H Khan","year":"2021","unstructured":"Khan H, Gupta A, Singh TG, Kaur A (2021a) Mechanistic insight on the role of leukotriene receptors in ischemic\u2013reperfusion injury. Pharmacol Rep 73(5):1240\u20131254. https:\/\/doi.org\/10.1007\/s43440-021-00258-8","journal-title":"Pharmacol Rep"},{"issue":"8","key":"1072_CR32","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1007\/s12035-021-02387-w","volume":"58","author":"H Khan","year":"2021","unstructured":"Khan H, Tiwari P, Kaur A, Singh TG (2021b) Sirtuin acetylation and deacetylation: a complex paradigm in neurodegenerative disease. Mol Neurobiol 58(8):3903\u20133917. https:\/\/doi.org\/10.1007\/s12035-021-02387-w","journal-title":"Mol Neurobiol"},{"key":"1072_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-021-03521-9","author":"H Khan","year":"2022","unstructured":"Khan H, Garg N, Singh TG, Kaur A, Thapa K (2022a) Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases. Neurochem Res. https:\/\/doi.org\/10.1007\/s11064-021-03521-9","journal-title":"Neurochem Res"},{"key":"1072_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2022.03.016","author":"H Khan","year":"2022","unstructured":"Khan H, Grewal AK, Singh TG (2022b) Pharmacological postconditioning by protocatechuic acid attenuates brain injury in ischemia-reperfusion (I\/R) mice model: Implications of nuclear factor erythroid-2-related factor pathway. Neuroscience. https:\/\/doi.org\/10.1016\/j.neuroscience.2022.03.016","journal-title":"Neuroscience"},{"key":"1072_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-022-01546-6","author":"H Khan","year":"2022","unstructured":"Khan H, Sharma K, Kumar A, Kaur A, Singh TG (2022c) Therapeutic implications of cyclooxygenase (COX) inhibitors in ischemic injury. Inflamm Res. https:\/\/doi.org\/10.1007\/s00011-022-01546-6","journal-title":"Inflamm Res"},{"key":"1072_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lfs.2015.07.017","volume":"137","author":"KI Kinoshita","year":"2015","unstructured":"Kinoshita KI, Tada Y, Muroi Y, Unno T, Ishii T (2015) Selective loss of dopaminergic neurons in the substantia nigra pars compacta after systemic administration of MPTP facilitates extinction learning. Life Sci 137:28\u201336. https:\/\/doi.org\/10.1016\/j.lfs.2015.07.017","journal-title":"Life Sci"},{"key":"1072_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/0891988710383571","author":"MEI Koran","year":"2014","unstructured":"Koran MEI (2014) Imaging and genetics of two amyloid related diseases: Alzheimer\u2019s disease and down syndrome. Vanderbilt Univ. https:\/\/doi.org\/10.1177\/0891988710383571","journal-title":"Vanderbilt Univ"},{"issue":"11","key":"1072_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1940-6207.CAPR-21-0208","volume":"14","author":"KJ Lee","year":"2021","unstructured":"Lee KJ, Chang WC, Chen X, Valiyaveettil J, Ramirez-Alcantara V, Gavin E, Musiyenko A, Madeira da Silva L, Annamdevula NS, Leavesley SJ, Ward A (2021) Suppression of colon tumorigenesis in mutant Apc mice by a novel PDE10 inhibitor that reduces oncogenic \u03b2-catenin. Cancer Prev Res 14(11):995\u20131008. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-21-0208","journal-title":"Cancer Prev Res"},{"key":"1072_CR39","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.283.5403.848","volume":"283","author":"L Li","year":"1999","unstructured":"Li L, Yee C, Beavo JA (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283:848\u2013851. https:\/\/doi.org\/10.1126\/science.283.5403.848","journal-title":"Science"},{"key":"1072_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neuropharm.2012.06.032","volume":"64","author":"TV Lipina","year":"2013","unstructured":"Lipina TV, Palomo V, Gil C, Martinez A, Roder JC (2013) Dual inhibitor of PDE7 and GSK-3\u2013VP1. 15 acts as antipsychotic and cognitive enhancer in C57BL\/6J mice. Neuropharmacology 64:205\u2013214. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.06.032","journal-title":"Neuropharmacology"},{"key":"1072_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/ndt.s4771","volume":"5","author":"HR Luo","year":"2009","unstructured":"Luo HR, Wu GS, Dong C, Arcos-Burgos M, Ribeiro L, Licinio J, Wong ML (2009) Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr Dis Treat 5:163. https:\/\/doi.org\/10.2147\/ndt.s4771","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1072_CR42","doi-asserted-by":"publisher","unstructured":"McCarthy DP, Richards MH, Miller SD (2012) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler\u2019s virus-induced demyelinating disease. In: Autoimmunity. Humana Press, Totowa, pp 381\u2013401. https:\/\/doi.org\/10.1007\/978-1-60761-720-4_19","DOI":"10.1007\/978-1-60761-720-4_19"},{"key":"1072_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2165\/00023210-200721100-00001","volume":"21","author":"EG McGeer","year":"2007","unstructured":"McGeer EG, McGeer PL (2007) The role of anti-inflammatory agents in Parkinson\u2019s disease. CNS Drugs 21:789\u2013797. https:\/\/doi.org\/10.2165\/00023210-200721100-00001","journal-title":"CNS Drugs"},{"key":"1072_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ana.10728","volume":"54","author":"PL McGeer","year":"2003","unstructured":"McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 54:599\u2013604. https:\/\/doi.org\/10.1002\/ana.10728","journal-title":"Ann Neurol"},{"key":"1072_CR203","doi-asserted-by":"publisher","first-page":"107357","DOI":"10.1016\/j.nlm.2020.107357","volume":"177","author":"S McQuown","year":"2001","unstructured":"McQuown S, Paes D, Baumg\u00e4rtel K, Prickaerts J, Peters M (2021) Pharmacological inhibition of phosphodiesterase 7 enhances consolidation processes of spatial memory. Neurobiol Learn Mem 177:107357. https:\/\/doi.org\/10.1016\/j.nlm.2020.107357","journal-title":"Neurobiol Learn Mem"},{"issue":"1","key":"1072_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep43545","volume":"7","author":"EM Medina-Rodr\u00edguez","year":"2017","unstructured":"Medina-Rodr\u00edguez EM, Bribi\u00e1n A, Boyd A, Palomo V, Pastor J, Lagares A, Gil C, Mart\u00ednez A, Williams A, de Castro F (2017) Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep 7(1):1\u201314. https:\/\/doi.org\/10.1038\/srep43545","journal-title":"Sci Rep"},{"issue":"1","key":"1072_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1043-2760(01)00523-9","volume":"13","author":"C Mehats","year":"2002","unstructured":"Mehats C, Andersen CB, Filopanti M, Jin SC, Conti M (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13(1):29\u201335. https:\/\/doi.org\/10.1016\/s1043-2760(01)00523-9","journal-title":"Trends Endocrinol Metab"},{"key":"1072_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2589276","author":"J Mendiola-Precoma","year":"2016","unstructured":"Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G (2016) Therapies for prevention and treatment of Alzheimer\u2019s disease. Biomed Res Int. https:\/\/doi.org\/10.1155\/2016\/2589276","journal-title":"Biomed Res Int"},{"key":"1072_CR48","doi-asserted-by":"publisher","unstructured":"Mercier J, Provins L, Hannestad J (2017). Progress and challenges in the development of PET ligands to aid CNS drug discovery. https:\/\/doi.org\/10.1016\/B978-0-12-409547-2.12437-0","DOI":"10.1016\/B978-0-12-409547-2.12437-0"},{"issue":"17","key":"1072_CR49","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1111\/bph.13192","volume":"172","author":"L Mestre","year":"2015","unstructured":"Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-Garc\u00eda JA, Alonso-Gil S, P\u00e9rez-Castillo A, Gil C, Mart\u00ednez A, Guaza C (2015) PDE 7 inhibitor TC 3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. Br J Pharmacol 172(17):4277\u20134290. https:\/\/doi.org\/10.1111\/bph.13192","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1072_CR205","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1021\/cn400166d","volume":"5","author":"JA Morales-Garcia","year":"2014","unstructured":"Morales-Garcia JA, Palomo V, Redondo M, Alonso-Gil S, Gil C, Martinez A, Perez-Castillo A (2014) Crosstalk between phosphodiesterase 7 and glycogen synthase kinase-3: two relevant therapeutic targets for neurological disorders. ACS Chem Neurosci 5(3):194\u2013204. https:\/\/doi.org\/10.1021\/cn400166d","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"1072_CR50","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/stem.2480","volume":"35","author":"JA Morales-Garcia","year":"2017","unstructured":"Morales-Garcia JA, Echeverry-Alzate V, Alonso-Gil S, Sanz-SanCristobal M, Lopez-Moreno JA, Gil C, Martinez A, Santos A, Perez-Castillo A (2017) Phosphodiesterase7 inhibition activates adult neurogenesis in hippocampus and subventricular zone in vitro and in vivo. Stem Cells 35(2):458\u2013472. https:\/\/doi.org\/10.1002\/stem.2480","journal-title":"Stem Cells"},{"issue":"2","key":"1072_CR204","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s12035-019-01745-z","volume":"57","author":"JA Morales-Garcia","year":"2020","unstructured":"Morales-Garcia JA, Alonso-Gil S, Santos \u00c1, Perez-Castillo A (2020) Phosphodiesterase 7 regulation in cellular and rodent models of Parkinson\u2019s disease. Mol Neurobiol 57(2):806\u2013822. https:\/\/doi.org\/10.1007\/s12035-019-01745-z","journal-title":"Mol Neurobiol"},{"issue":"3","key":"1072_CR51","doi-asserted-by":"publisher","first-page":"e004740","DOI":"10.1161\/CIRCHEARTFAILURE.117.004740","volume":"11","author":"T Nakamura","year":"2018","unstructured":"Nakamura T, Zhu G, Ranek MJ, Kokkonen-Simon K, Zhang M, Kim GE, Tsujita K, Kass DA (2018) Prevention of PKG-1\u03b1 oxidation suppresses antihypertrophic\/antifibrotic effects from PDE5 inhibition but not sGC stimulation. Circ Heart Fail 11(3):e004740. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004740","journal-title":"Circ Heart Fail"},{"issue":"7","key":"1072_CR52","doi-asserted-by":"publisher","first-page":"710","DOI":"10.17485\/ijst\/2010\/v3i7.1","volume":"3","author":"J Nandhakumar","year":"2010","unstructured":"Nandhakumar J, Tyagi MG (2010) Evaluation of seizure activity after phospho-diesterase and adenylate cyclase inhibition (SQ22536) in animal models of epilepsy. Indian J Sci Technol 3(7):710\u2013717. https:\/\/doi.org\/10.17485\/ijst\/2010\/v3i7.1","journal-title":"Indian J Sci Technol"},{"issue":"23","key":"1072_CR53","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1212\/WNL.0000000000000498","volume":"82","author":"MD Nelson","year":"2014","unstructured":"Nelson MD, Rader F, Tang X, Tavyev J, Nelson SF, Miceli MC, Elashoff RM, Sweeney HL, Victor RG (2014) PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 82(23):2085\u20132091. https:\/\/doi.org\/10.1212\/WNL.0000000000000498","journal-title":"Neurology"},{"issue":"3","key":"1072_CR54","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","volume":"100","author":"K Omori","year":"2007","unstructured":"Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100(3):309\u2013327. https:\/\/doi.org\/10.1161\/01.RES.0000256354.95791.f1","journal-title":"Circ Res"},{"key":"1072_CR55","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1093\/brain\/awh625","volume":"128","author":"CF Orr","year":"2005","unstructured":"Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM (2005) A possible role for humoral immunity in the pathogenesis of Parkinson\u2019s disease. Brain 128:2665\u20132674. https:\/\/doi.org\/10.1093\/brain\/awh625","journal-title":"Brain"},{"key":"1072_CR56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neurobiolaging.2018.01.019","volume":"65","author":"NS Patel","year":"2018","unstructured":"Patel NS, Klett J, Pilarzyk K, ik Lee D, Kass D, Menniti FS, Kelly MP (2018) Identification of new phosphodiesterase 9A (PDE9A) isoforms and how their expression and subcellular compartmentalization in brain changes across the lifespan. Neurobiol Aging 65:217. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.01.019","journal-title":"Neurobiol Aging"},{"key":"1072_CR57","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ejmech.2018.03.046","volume":"150","author":"T Peng","year":"2018","unstructured":"Peng T, Gong J, Jin Y, Zhou Y, Tong R, Wei X, Bai L, Shi J (2018) Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem 150:742\u2013756. https:\/\/doi.org\/10.1016\/j.ejmech.2018.03.046","journal-title":"Eur J Med Chem"},{"issue":"9","key":"1072_CR206","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.neurobiolaging.2013.03.011","volume":"34","author":"R Perez-Gonzalez","year":"2013","unstructured":"Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, P\u00e9rez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging 34(9):2133\u20132145. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.03.011","journal-title":"Neurobiol Aging"},{"key":"1072_CR58","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","volume":"182","author":"S P\u00e9rez-Torres","year":"2003","unstructured":"P\u00e9rez-Torres S, Cort\u00e9s R, Tolnay M, Probst A, Palacios JM, Mengod G (2003) Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer\u2019s disease brains examined by in situ hybridization. Exp Neurol 182:322\u2013334. https:\/\/doi.org\/10.1016\/S0014-4886(03)00042-6","journal-title":"Exp Neurol"},{"issue":"7","key":"1072_CR59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/biomedicines9070703","volume":"9","author":"L Ponsaerts","year":"2021","unstructured":"Ponsaerts L, Alders L, Schepers M, de Oliveira RM, Prickaerts J, Vanmierlo T, Bronckaers A (2021) Neuroinflammation in ischemic stroke: inhibition of cAMP-specific phosphodiesterases (PDEs) to the rescue. Biomedicines 9(7):703. https:\/\/doi.org\/10.3390\/biomedicines9070703","journal-title":"Biomedicines"},{"key":"1072_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuroscience.2012.05.050","volume":"251","author":"J Pozueta","year":"2013","unstructured":"Pozueta J, Lefort R, Shelanski ML (2013) Synaptic changes in Alzheimer's disease and its models. Neuroscience 251:51\u201365. https:\/\/doi.org\/10.1016\/j.neuroscience.2012.05.050","journal-title":"Neuroscience"},{"key":"1072_CR61","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejmech.2011.10.040","volume":"47","author":"M Redondo","year":"2012","unstructured":"Redondo M, Zarruk JG, Ceballos P, P\u00e9rez DI, P\u00e9rez C, Perez-Castillo A, Moro MA, Brea J, Val C, Cadavid MI, Loza MI (2012) Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. Eur J Med Chem 47:175\u2013185. https:\/\/doi.org\/10.1016\/j.ejmech.2011.10.040","journal-title":"Eur J Med Chem"},{"key":"1072_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.brainres.2009.10.071","volume":"1309","author":"AK Rehni","year":"2010","unstructured":"Rehni AK, Singh TG, Bhateja P, Singh N, Arora S (2010) Involvement of cyclic adenosine diphosphoribose receptor activation in ischemic preconditioning induced protection in mouse brain. Brain Res 1309:75\u201382. https:\/\/doi.org\/10.1016\/j.brainres.2009.10.071","journal-title":"Brain Res"},{"issue":"4","key":"1072_CR63","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2174\/157015911798376271","volume":"9","author":"GW Reierson","year":"2011","unstructured":"Reierson GW, Guo S, Mastronardi C, Licinio J, Wong ML (2011) cGMP signaling, phosphodiesterases and major depressive disorder. Curr Neuropharmacol 9(4):715\u2013727. https:\/\/doi.org\/10.2174\/157015911798376271","journal-title":"Curr Neuropharmacol"},{"issue":"12","key":"1072_CR64","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1021\/acschemneuro.0c00244","volume":"11","author":"G Ribaudo","year":"2020","unstructured":"Ribaudo G, Ongaro A, Zagotto G, Memo M, Gianoncelli A (2020) Therapeutic potential of phosphodiesterase inhibitors against neurodegeneration: the perspective of the medicinal chemist. ACS Chem Neurosci 11(12):1726\u20131739. https:\/\/doi.org\/10.1021\/acschemneuro.0c00244","journal-title":"ACS Chem Neurosci"},{"issue":"21","key":"1072_CR65","doi-asserted-by":"publisher","first-page":"11971","DOI":"10.3390\/ijms222111971","volume":"22","author":"A Sharma","year":"2021","unstructured":"Sharma A, Khan H, Singh TG, Grewal AK, Najda A, Kawecka-Radomska M, Kamel M, Altyar AE, Abdel-Daim MM (2021a) Pharmacological modulation of ubiquitin-proteasome pathways in oncogenic signaling. Int J Mol Sci 22(21):11971. https:\/\/doi.org\/10.3390\/ijms222111971","journal-title":"Int J Mol Sci"},{"key":"1072_CR207","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/693010","volume-title":"Abstract and applied analysis","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, Lai S, Ma Y, Luo X (2012) The space global weak solutions to the weakly dissipative camassa- holm equation. In: Abstract and applied analysis, vol 2012. Hindawi. https:\/\/doi.org\/10.1155\/2012\/693010"},{"key":"1072_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mito.2021.04.004","volume":"59","author":"VK Sharma","year":"2021","unstructured":"Sharma VK, Singh TG, Mehta V (2021b) Stressed mitochondria: a target to intrude Alzheimer\u2019s disease. Mitochondrion 59:48\u201357. https:\/\/doi.org\/10.1016\/j.mito.2021.04.004","journal-title":"Mitochondrion"},{"issue":"6","key":"1072_CR67","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1124\/mol.104.002246","volume":"66","author":"SJ Smith","year":"2004","unstructured":"Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA (2004) Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66(6):1679\u20131689. https:\/\/doi.org\/10.1124\/mol.104.002246","journal-title":"Mol Pharmacol"},{"key":"1072_CR68","doi-asserted-by":"publisher","unstructured":"Soni NO (2019) Current and future clinical application-phosphodiesterase (PDEs)-inhibitors. https:\/\/doi.org\/10.20959\/wjpps20197-14233","DOI":"10.20959\/wjpps20197-14233"},{"issue":"11","key":"1072_CR69","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1021\/acs.jmedchem.1c00115","volume":"64","author":"J Sun","year":"2021","unstructured":"Sun J, Xiao Z, Haider A, Gebhard C, Xu H, Luo HB, Zhang HT, Josephson L, Wang L, Liang SH (2021) Advances in cyclic nucleotide phosphodiesterase-targeted PET imaging and drug discovery. J Med Chem 64(11):7083\u20137109. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00115","journal-title":"J Med Chem"},{"issue":"6","key":"1072_CR208","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1471-4159.2012.07866.x","volume":"122","author":"J Sus\u00edn","year":"2012","unstructured":"Sus\u00edn C, Morales\u2010Garcia JA, Aguilar\u2010Morante D, Palomo V, Sanz\u2010Sancristobal M, Alonso\u2010Gil S, Gil C, Santos A, Martinez A, Perez\u2010Castillo A (2012) The new iminothiadiazole derivative VP1. 14 ameliorates hippocampal damage after an excitotoxic injury. J Neurochem 122(6):1193\u20131202. https:\/\/doi.org\/10.1111\/j.1471-4159.2012.07866.x","journal-title":"J Neurochem"},{"issue":"17","key":"1072_CR70","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.3390\/ijms21176118","volume":"21","author":"M Szczypka","year":"2020","unstructured":"Szczypka M (2020) Role of phosphodiesterase 7 (PDE7) in T cell activity. Effects of selective PDE7 inhibitors and dual PDE4\/7 inhibitors on T cell functions. Int J Mol Sci 21(17):6118. https:\/\/doi.org\/10.3390\/ijms21176118","journal-title":"Int J Mol Sci"},{"key":"1072_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2007.07.004","volume":"208","author":"MG Tansey","year":"2007","unstructured":"Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson\u2019s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208:1\u201325. https:\/\/doi.org\/10.1016\/j.expneurol.2007.07.004","journal-title":"Exp Neurol"},{"key":"1072_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118975","volume":"267","author":"K Thapa","year":"2021","unstructured":"Thapa K, Khan H, Sharma U, Grewal AK, Singh TG (2021) Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases. Life Sci 267:118975. https:\/\/doi.org\/10.1016\/j.lfs.2020.118975","journal-title":"Life Sci"},{"issue":"8","key":"1072_CR210","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1096\/fj.09-152611","volume":"24","author":"F Torri","year":"2010","unstructured":"Torri F, Akelai A, Lupoli S, Sironi M, Amann\u2010Zalcenstein D, Fumagalli M, Fiume CD, Ben\u2010Asher E, Kanyas K,\nCagliani R, Cozzi P (2010) Fine mapping of AHI1 as a schizophrenia susceptibility gene: from association to evolutionary evidence. FASEB J 24(8):3066\u20133082. https:\/\/doi.org\/10.1096\/fj.09-152611","journal-title":"FASEB J"},{"issue":"27","key":"1072_CR73","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.1073\/pnas.1007088107","volume":"107","author":"N Volakakis","year":"2010","unstructured":"Volakakis N, Kadkhodaei B, Joodmardi E, Wallis K, Panman L, Silvaggi J, Spiegelman BM, Perlmann T (2010) NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci 107(27):12317\u201312322. https:\/\/doi.org\/10.1073\/pnas.1007088107","journal-title":"Proc Natl Acad Sci"},{"issue":"44","key":"1072_CR74","doi-asserted-by":"publisher","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice. J Neurosci 30(44):14708\u201314718. https:\/\/doi.org\/10.1523\/JNEUROSCI.1637-10.2010","journal-title":"J Neurosci"},{"key":"1072_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.intimp.2016.06.004","volume":"38","author":"C Xu","year":"2016","unstructured":"Xu C, Wyman AR, Alaamery MA, Argueta SA, Ivey FD, Meyers JA, Lerner A, Burdo TH, Connolly T, Hoffman CS, Chiles TC (2016) Anti-inflammatory effects of novel barbituric acid derivatives in T lymphocytes. Int Immunopharmacol 38:223\u2013232. https:\/\/doi.org\/10.1016\/j.intimp.2016.06.004","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1072_CR76","doi-asserted-by":"publisher","first-page":"F576","DOI":"10.1152\/ajprenal.00477.2019","volume":"318","author":"M Xu","year":"2020","unstructured":"Xu M, Yu X, Meng X, Huang S, Zhang Y, Zhang A, Jia Z (2020) Inhibition of PDE4\/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 318(3):F576\u2013F588. https:\/\/doi.org\/10.1152\/ajprenal.00477.2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"1072_CR77","doi-asserted-by":"publisher","DOI":"10.4103\/2152-7806.169561","author":"S Zarei","year":"2015","unstructured":"Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A (2015) A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. https:\/\/doi.org\/10.4103\/2152-7806.169561","journal-title":"Surg Neurol Int"},{"issue":"9","key":"1072_CR78","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4161\/org.26710","volume":"59","author":"H Zhang","year":"2018","unstructured":"Zhang H, Yang Z, Lin T, Wu Y, Zou T, Zhang Y (2018) ARL2 regulates trafficking and expression of isoprenylated proteins and is crucial for development of photoreceptor outer segments. Invest Ophthalmol vis Sci 59(9):963\u2013963. https:\/\/doi.org\/10.4161\/org.26710","journal-title":"Invest Ophthalmol vis Sci"},{"key":"1072_CR79","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","volume":"176","author":"P Zhang","year":"2019","unstructured":"Zhang P, Xu S, Zhu Z, Xu J (2019) Multi-target design strategies for the improved treatment of Alzheimer\u2019s disease. Eur J Med Chem 176:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.020","journal-title":"Eur J Med Chem"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-022-01072-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T20:16:58Z","timestamp":1669407418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-022-01072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1007\/s10787-022-01072-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,22]]},"assertion":[{"value":"1 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}